Watanabe Jota, Scornik Juan C
Department of Pathology, University of Florida College of Medicine, Gainesville, Florida, USA.
Am J Transplant. 2005 Nov;5(11):2786-90. doi: 10.1111/j.1600-6143.2005.01056.x.
The immediate effects of IVIG can be due to the presence of anti-idiotypic antibodies or inhibition of complement, but there is limited data about these possible mechanisms specifically on HLA antibodies (HLA Abs). Potential blocking activity of IVIG on HLA Ab binding and complement activation was investigated by flow cytometry. IVIG did not inhibit the IgG binding of any of 23 sera from sensitized patients containing Abs to several different HLA specificities. In contrast, IVIG produced significant dose-dependent complement inhibition. Low IVIG concentrations could be inhibitory if there was little C3 activation, but high concentrations were needed when C3 was activated more efficiently. The data do not support any significant contribution of anti-idiotypic antibodies against HLA Abs to the activity of IVIG. The results also highlight a relationship between the magnitude of C activation and the C inhibitory effect of IVIG.
静脉注射免疫球蛋白（IVIG）的即时效应可能归因于抗独特型抗体的存在或补体的抑制，但关于这些可能机制，特别是针对人类白细胞抗原抗体（HLA抗体）的具体数据有限。通过流式细胞术研究了IVIG对HLA抗体结合和补体激活的潜在阻断活性。IVIG并未抑制23份来自致敏患者的血清中任何一份血清的IgG结合，这些血清含有针对几种不同HLA特异性的抗体。相反，IVIG产生了显著的剂量依赖性补体抑制作用。如果C3激活较少，低浓度的IVIG可能具有抑制作用，但当C3更有效地激活时，则需要高浓度。数据不支持抗独特型抗体对HLA抗体在IVIG活性方面有任何显著贡献。结果还突出了C激活程度与IVIG的C抑制作用之间的关系。
